蛋白激酶B基因内含子区多态性与西酞普兰抗抑郁治疗的关联研究  

An association study between protein kinase B gene intron polymorphism and citalopram antidepressant effect

作　　者：白丽娟[1] 王彦芳[1] 刘志芬[1] 李霞[2] 于宏春[1] 于瑞[3] 杨晋民 张克让[1] 

机构地区：[1]山西医科大学第一医院精神卫生科,太原030001 [2]中国人民武装警察部队山西省总队医院 [3]山西省大同市同煤集团三医院精神卫生科 [4]长治市安神医院

出　　处：《中华行为医学与脑科学杂志》2010年第3期193-196,共4页Chinese Journal of Behavioral Medicine and Brain Science

基　　金：国家自然科学基金（30770770）;山西省科技攻关项目（2007031091-3）;国家人事部留学回国人员科研资助项目（2007-48）;山西省自然科学基金（2007011120）

摘　　要：目的探讨蛋白激酶Bd（PKBα）基因第1，2，4内含子区4个单核甘酸多态性与西酞普兰抗抑郁疗效及副反应之间的关联。方法收集符合美国精神障碍诊断与统计手册第4版（DSM—IV）重性抑郁障碍诊断标准的患者，共104例。使用西酞普兰抗抑郁治疗，在治疗后1周、2周、4周时评定相关量表，应用聚合酶联反应（PCR）和DNA直接测序技术，检测PKB多态性位点基因型；使用SPSS13．0统计软件进行分析。结果①PKBα rs2494738与西酞普兰抗抑郁疗效之间相关联（等位基因：OR=0．139，P=0．011）；携带G等位基因抑郁症患者西酞普兰治疗抗抑郁疗效优于携带A等位基因者。②rs2494738基因型可能与口干副反应弱关联（Х^2=6．730，P=0．035）。结论PKBα rs2494738位点可能与西酞普兰治疗抗抑郁疗效及某些副反应之间有关联。Objective To examine the association between protein kinase Bα gene first,second and forth intron polymorphism and citalopram antidepressant clinical efficacy and side effects. Methods The subjects comprised 104 patients according to the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition （DSM-IV） criteria for major depressive disorder. The clinical efficacy and side effects were assessed on 1 week,2 weeks,4 weeks after citalopram treatment. PCR and DNA sequencing analysis were used to detect the genotype of PKB. SPSS13.0 statistic software was used to statistic analysis. Results ① An association was found between PKBα rs2494738 and citalopram antidepressant effect （alleles：OR = 0.139, P= 0.011 ） ;and the major depressive disorders patient carrying G alleles showed the better effect of citalopram treatment than individual carrying A allele. ②A weak association was revealed between the genotype of rs2494738 and adverse dry mouth（ Х^2 = 6. 730, P = 0. 035 ）. Conclusion The PKBα rs2494738 polymorphism may associate with citalopram antidepressant effica- cy and side effects.

关 键 词：重性抑郁障碍 蛋白激酶Bα 单核苷酸多态性 西酞普兰 

分 类 号：R749.4[医药卫生—神经病学与精神病学]